(ROIV) Roivant Sciences Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ROIV) Roivant Sciences Ltd. Complete Analysis Pack
Actionable Strategy Starts Here
This Roivant Sciences Ltd. BCG Matrix helps you quickly assess how the company’s business units or products fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
IMVT-1402 lead FcRn asset
Roivant’s Immunovant stake is a high-beta call on IMVT-1402, a next-gen FcRn antibody in a large autoimmune market. Roivant owned about 76% of Immunovant in FY2025, and the program is aimed at high-unmet-need diseases like Graves’ disease and myasthenia gravis. If clinical data stay clean, it could become a major future value driver.
Brepocitinib lead autoimmune asset
Brepocitinib is Priovant’s lead autoimmune asset and a dual TYK2/JAK1 inhibitor, giving it two validated inflammation targets in one molecule.
That multi-indication optionality matters in biopharma: one late-stage win can support use across more than 1 disease and build a franchise, not just a single product.
If Phase 3 data stay strong, Brepocitinib can fit the Stars bucket for Roivant Sciences Ltd. because it combines high-growth demand with real upside from a larger addressable market.
Immunovant equity stake
Roivant Sciences Ltd. keeps a major economic interest in Immunovant, so it captures upside from the FcRn platform without funding all of the R&D itself. Immunovant’s lead asset, batoclimab, showed an FcRn class effect in 2025 data, and the stock still gives Roivant leveraged exposure to a high-growth area.
That mix of owned upside and limited capital burden makes this one of Roivant Sciences Ltd.’s clearest Star-type holdings in the BCG Matrix.
Priovant equity stake
Roivant’s Priovant stake is a star-like asset because it links Roivant to upside in autoimmune and dermatology programs, where positive data can expand across multiple indications. Priovant is still clinical-stage, so value depends on readouts, but the platform optionality and Roivant’s equity exposure give it leveraged growth potential.
- Autoimmune and dermatology upside
- Multi-indication platform optionality
- High leverage to trial success
Multiple late stage clinical shots
Roivant Sciences Ltd. ended fiscal 2025 with several active late-stage clinical programs in immunology and inflammation, so this stays a catalyst-heavy Star profile, not a harvest story yet. The company is still funding high development intensity, which fits Star assets that need capital before cash flow scales.
- Late-stage shots drive near-term value catalysts.
- Immunology and inflammation remain core focus areas.
- 2025 still looks like build phase, not monetization.
Roivant’s Autoimmune Stars Could Re-rate Fast
Roivant Sciences Ltd.’s Stars are its autoimmune bets, led by Immunovant and Priovant, where late-stage data can still re-rate value fast. In FY2025, Roivant owned about 76% of Immunovant, giving leveraged upside to IMVT-1402 while limiting full R&D burden.
| Asset | FY2025 signal | BCG view |
|---|---|---|
| Immunovant | ~76% owned | Star |
What is included in the product
Detailed Word Document
Roivant’s BCG Matrix maps its pipeline and platforms to spotlight growth bets, cash-generators, and assets to hold or trim.
Editable Excel File
Quick BCG matrix for Roivant Sciences Ltd. to spot wins, cash drains, and portfolio gaps at a glance
Reference Sources
Provides a credible source trail for Roivant Sciences Ltd., helping users verify key claims fast and make better decisions with less uncertainty.
Cash Cows
Telavant sale $7.1B enterprise value
Roivant Sciences Ltd. monetized Telavant in Roche’s $7.1 billion enterprise value deal, turning a non-core asset into a major liquidity event. The transaction delivered a large cash inflow plus equity-linked consideration, making it Roivant Sciences Ltd.’s clearest corporate-level cash cow. In BCG terms, this is classic "milk the asset" execution: high value created, then harvested.
Dermavant sale $1.2B cash
Roivant Sciences Ltd. sold Dermavant to Organon for $1.2 billion in cash, turning a dermatology asset into immediate liquidity. That is classic cash cow behavior: a mature, monetizable asset was harvested instead of funded longer. The deal gave Roivant a large cash inflow with no equity dilution.
Myovant monetization relugolix franchise
Roivant monetized Myovant after relugolix reached the market, which is classic cash-cow behavior: sell once growth cools and cash flow becomes predictable. Relugolix is already commercial, with ORGOVYX approved in 2020 and Myfembree in 2021, so the franchise had moved beyond pure R&D risk. That fits a mature asset with visible sales and lower reinvestment needs.
Urovant monetization vibegron franchise
Roivant’s Urovant/Vibegron asset fits the "cash cow" bucket because Gemtesa is already approved and serves a durable overactive bladder market, so it is easier to harvest than to build. Roivant monetized the franchise instead of funding it for growth, which helped convert an operating asset into capital for newer shots on goal. This kind of exit supports Roivant’s model: recycle mature cash flows into pipeline bets.
- Approved product, lower launch risk
- Established demand, steady monetization
- Exit frees capital for pipeline
- Cash cows fund new growth bets
Multi billion liquidity base
Roivant Sciences Ltd. ended fiscal 2025 with about $4.0 billion of cash, cash equivalents, and marketable securities, giving it a real cash-cow layer in the BCG sense. That liquidity came from asset sales and divestitures, which lowered the need for repeated equity raises and diluted fewer holders. With no meaningful debt load, the balance sheet itself helps fund new bets and platform expansion.
- FY2025 liquidity: about $4.0B
- Divestitures boosted cash
- Less reliance on dilution
- Balance sheet funds growth
Roivant’s Cash Cows Fuel Its Next Growth Bets
Roivant Sciences Ltd. cash cows are its monetized late-stage assets, led by Telavant, Dermavant, and Myovant, which converted mature programs into major cash inflows. FY2025 ended with about $4.0 billion in cash, cash equivalents, and marketable securities, so Roivant Sciences Ltd. can fund new bets with less dilution. That is the core BCG cash cow role: harvest mature assets and recycle the proceeds.
| Asset | Value |
|---|---|
| Telavant | $7.1B EV |
| Dermavant | $1.2B cash |
| FY2025 liquidity | ~$4.0B |
Preview Before You Purchase
Roivant Sciences Ltd. Reference Sources
The Roivant Sciences Ltd. BCG Matrix preview you see here is the exact same file you’ll receive after purchase. There are no mockups, watermarks, or placeholder pages—just the full, professionally formatted report. Once purchased, the document is ready for immediate download and use. What you preview is what you get.
Dogs
Axovant legacy neuro unit
Axovant was one of Roivant Sciences Ltd.'s early high-profile neuro bets, but its lead Alzheimer’s drug intepirdine failed in Phase 3 in 2017, and the unit never became a durable commercial franchise. That profile fits a Dog in the BCG Matrix: low growth, weak share, and little cash generation. Roivant later shifted capital to newer programs, while the Axovant legacy remains a reminder of a high-burn, low-return asset.
Alyvant legacy immunology unit
Alyvant never became a core growth engine for Roivant Sciences Ltd.; public filings do not show it as a separate revenue driver, so its scale stayed too small to matter. Its low strategic fit and limited stand-alone economics made it a Dog in BCG terms, not a market winner. Capital was better directed to higher-priority assets with clearer 2025-2026 value creation paths.
Enzyvant legacy rare disease unit
Enzyvant, Roivant Sciences Ltd.’s legacy rare disease unit, never became a major value creator. In FY2025 terms, it stayed outside Roivant’s main growth lanes, so it fits a Dogs profile: low growth, low share, and little capital pull.
Pulmovant legacy respiratory unit
Pulmovant fits the "dogs" box because Roivant Sciences Ltd. never turned it into a leading pulmonary franchise, and the respiratory path stayed hard to scale. In BCG terms, a non-core unit with weak traction and no clear market lead is a capital drain, not a growth engine.
Respiratory R&D is slow and expensive: late-stage trials often need hundreds of patients and many years, so weak programs can keep burning cash without moving the revenue needle.
- Weak franchise position
- Limited commercial traction
- High development burden
- Low strategic fit
Spirovant legacy cystic fibrosis effort
Spirovant never turned its cystic fibrosis work into a market leader, and that matters in a field with only about 105,000 patients worldwide and a small set of expert centers. With Vertex still dominant and the CF space highly technical, Spirovant’s weak commercial odds fit the dog bucket in Roivant Sciences Ltd.'s BCG view.
- No approved CF product.
- Small, specialized patient pool.
- Dominant incumbent competition.
- Low return on future spend.
Roivant’s Dogs: Legacy Assets with Weak Growth and Cash Returns
Roivant Sciences Ltd.'s Dogs are legacy, low-share assets with weak cash pull, like Axovant, Alyvant, Enzyvant, Pulmovant, and Spirovant. Axovant’s intepirdine failed Phase 3 in 2017, and Spirovant faced a cystic fibrosis market of about 105,000 patients worldwide, still dominated by Vertex. These units fit low-growth, low-return buckets in FY2025-2026 capital planning.
| Unit | Dog signal |
|---|---|
| Axovant | Phase 3 failure |
| Spirovant | Small CF pool |
Question Marks
IMVT-1402 Graves disease
Graves disease affects about 1% of the U.S. population and is the leading cause of hyperthyroidism, with women up to 7 to 8 times more likely to develop it. The market is still growing because many patients need better options than antithyroid drugs, radioiodine, or surgery.
IMVT-1402 is still in development and has no commercial sales yet, so it has zero market share today. That makes it a clear Question Mark in Roivant Sciences Ltd.'s BCG Matrix: high-growth potential, but no proven revenue base yet.
IMVT-1402 myasthenia gravis
IMVT-1402 sits in an attractive but still contested myasthenia gravis market, with global prevalence often estimated at about 100 to 350 per million people. Roivant Sciences Ltd. has no sales base from this asset yet, so the BCG case is still "question mark" rather than "star." It needs clear phase data and a path to approval before it can move up the matrix.
IMVT-1402 Sjogren disease
Sjögren disease affects about 0.5% to 1% of adults, and there is no approved FcRn leader in this area, so IMVT-1402 targets a real unmet need. The upside is clear, but commercial uptake is still unproven because physician adoption, payer coverage, and long-term efficacy data are not yet settled. That puts Roivant Sciences Ltd. in question mark territory: high potential, high uncertainty.
Brepocitinib non infectious uveitis
Brepocitinib in non infectious uveitis sits in a specialized inflammatory eye market, but Roivant Sciences Ltd. still needs clear clinical and regulatory proof before it can scale. That keeps it in BCG Matrix Question Marks: high market promise, but high execution risk.
As of 2026, it remains a development-stage bet, so the value case depends on trial data, safety, and FDA/EMA feedback rather than current sales. One clean read: no approval means no revenue stream yet.
- Specialized, high-value eye inflammation niche
- Still needs clinical validation
- Regulatory risk remains the main hurdle
- High upside, but not de-risked
Brepocitinib dermatomyositis and cutaneous sarcoidosis
Brepocitinib in dermatomyositis and cutaneous sarcoidosis fits a question mark: both are rare autoimmune uses with limited current share, but they can scale if trial data leads to approval. Roivant Sciences Ltd. still has to turn clinical signals into payer-backed uptake, and that step usually decides whether a question mark becomes a star. As of fiscal 2025, the value is still mainly option value, not sales.
- Rare diseases = low share, high upside.
- Approval and uptake still drive value.
Roivant’s Question Marks Need Trial Proof
Roivant Sciences Ltd.'s question marks are still pre-revenue assets with upside, but no sales proof yet. IMVT-1402 targets Graves disease, myasthenia gravis, and Sjögren disease, while brepocitinib targets non infectious uveitis, dermatomyositis, and cutaneous sarcoidosis. In fiscal 2025, the value case stayed tied to trial data, approval risk, and payer uptake, not current revenue.
| Asset | Status | 2025/2026 signal |
|---|---|---|
| IMVT-1402 | Question Mark | No sales; phase data needed |
| Brepocitinib | Question Mark | Clinical proof still pending |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.